retatrutide triple agonist gip glp-1 glucagon phase 3 2025 The data just dropped — and is rewriting what's possible in obesity medicine. 🧬 TRIUMPH-1 just released results, and the numbers are unlike anything we've seen from a medication: Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

The surprising science and sobering risks revealed.

hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.

veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight lossthey could also fight addiction itself